Pharma Journalist

5th Microbiome Movement – Skin Health & Dermatology Summit
2022-09-13 - 2022-09-15 | Four Points by Sheraton Boston Logan Airport Revere, 407 Squire Rd, Revere, MA, 02151, United States
Translating Scientific Methodologies Addressing the Skin Microbiome into Commercially Viable Dermatological Therapeutics & Cosmetic Products
Skin microbiome research is continuing to gain increasing market traction from a number of stakeholders, including drug developers and cosmetic brands. For investment and progress to continue, it is vital to meet and connect with the key opinion leaders in the space.
Now in its fifth year, the Microbiome Movement – Skin Health & Dermatology Summit will unite the field’s leaders from academia and industry to address the unique scientific and commercial challenges of working in the skin microbiome. This meeting will provide a platform for crucial discussions which will hasten the development of microbiome-targeting therapeutics and cosmetics that focus on characterization, clinical testing, and product commercialization.
This is your opportunity to connect with 100+ collaborative thought leaders in the skin microbiome field from academics, drug developers, cosmeceutical developers, cosmetic and consumer brands, to obtain a holistic view of the microbiome dermatology landscape that will revolutionise your product pipeline.
Find out more about the meeting, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/nzhrvy
Or become one of our event partners and showcase your company’s latest technologies and solutions! Get in touch with us directly or request a partnership prospectus here: https://ter.li/9kybuv
We look forward to welcoming you to Boston in September!

7th CAR-TCR Summit
2022-09-19 - 2022-09-23 | Boston, MA
Back to Boston with a bang! With 1,500 CAR and TCR developers, 200 speakers, 150 live presentations, 20 hours of networking and more surprises in store, the 7th CAR-TCR Summit will be the BIGGEST ever.
Gain end-to-end insights from industry giants and the innovators bringing disruptive technologies from bench to bedside and from vein to vein.
Discuss everything from novel allogeneic approaches with enhanced safety considerations, the latest in vivo gene engineering techniques, and advances in CMC and analytics to ensure the development of high-quality cell products.
With your industry reuniting in-person for the first time since 2019 to discuss leveraging the powerful potential of iPSC platforms, learnings from our successes and pitfalls, and manufacturing automation innovations for large scale consistent production, you can’t afford to miss the 7th Annual CAR-TCR Summit as we bring you more speakers, more content and more exclusive insights than ever before!
To know more visit: https://ter.li/km5zwy

2nd Annual Aseptic Processing Conference
2022-09-19 - 2022-09-20 | London, UK
2nd Annual Aseptic Processing Conference
Conference: 19 – 20 September 2022
Workshop: 21 September 2022
London, UK
http://www.asepticprocessing.co.uk/PJWL

Sponsored by: Dec Group, Rapid Micro Biosystems, Raumedic and STERIS

Conference Chairman: James Drinkwater, Head of Aseptic Processing Special Interest Group PHSS and Head of GMP Compliance, F Ziel GMBH
Driving a Holistic Approach to Assurance of Product Sterility through Aseptic Manufacturing following QRM Principles
SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference, this year taking place in London, on the 19 and 20 September 2022.
The Aseptic processing industry has seen consistent growth in recent years, with advances in innovative therapeutics, the introduction of novel techniques and personnel protocols, the integration of robotics and automation in filling lines, and rise of rapid microbiological methods being just a few of the factors driving this growth.
The Aseptic Processing equipment market was approaching a valuation of 10 billion USD in 2015, and is projected to exceed 12 billion USD in value by next year, then to far surpass a total market value of 50 billion USD before the end of the decade.
Join us to discuss and address the Guidance and Regulation including the EU GMP Annex 1, environmental control delving into the contamination control strategy, Pharma moving forward 4.0 covering data integrity and data consistency, robotics in aseptic processing and exploring the continued aseptic processing development in Annex 1 and environmental monitoring
This event is CPD Accredited
Event Hashtag: #AsepticProcessing
Benefits of Attending:

Discuss the revisions and the impact of Annex 1 on aseptic manufacturing
Explore the applications of rapid micro methods in the manufacture of sterile products
Discover a risk-based approach to cleaning and disinfection
Delve into case studies of competence in global aseptic manufacturing
Uncover the journey of isolation technology in a large biotech pharmaceutical plant
Analyse the new abilities of robotics and automation through their integration into aseptic technique

Who Should Attend?

Validation Managers
Senior Microbiologists
Senior QA’s and QC’s
Quality Control Managers
Heads of GMP Compliance
Quality Assurance Experts
Technical Operations Leads
Leaders in Sterility Assurance
Cleanroom Managers
Regulatory Affairs Managers
Production Managers
Quality Systems Managers
Heads of Quality Compliance
Process Leaders
Senior Auditors
Bioprocess Research & Development

PLUS – Post-Conference Workshop on 21 September 2022…
Implementation Strategy of Annex 1 in New or Existing Facilities
Led by: Richard Denk, Senior Consultant Aseptic Processing & Containment, Skan AG
View the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL

Pre-Filled Syringes San Francisco
2022-09-19 - 2022-09-20 | Hyatt Centric, Fisherman’s Wharf, San Francisco, CA, 94133, United States
SAE Media Group’s 3rd Annual Conference
September 19 – 20, 2022 | San Francisco, CA, USA
————————————————————————-
The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.

This year’s conference will be assessing the latest developments in new technologies for next generation device design, including computational simulation approaches forming the digital revolution of devices design. Furthermore, the latest advances in digital combination product development will be explored through the lens of lifecycle management and user-centric combination products. Leading experts from big pharma will be presenting case studies on recent advances in platform approaches in drug delivery devices and smart devices, while a panel discussion will explore the emerging opportunities of platforms for injectable devices. With recent developments in industry regulations and guidance, the 2022 agenda will give an international insight into the global regulatory environment and leading FDA representatives will address the key standards to be aware of in injectable device development.
Over recent years we have seen the need for injectable devices to adapt to novel therapeutics. Our expert industry thought leaders will present case studies and updates to the industry’s approach to injectable delivery for novel drug products. Furthermore, our speakers will be assessing the key considerations for primary packaging and CMC approaches to injectable device development.
As part of SAE Media Group’s leading injectable drug delivery portfolio, this event is not to be missed.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
To know more visit: http://www.prefilled-sanfrancisco.com/pharmajournalistwl

mRNA Process Development & Manufacturing Summit
2022-09-20 - 2022-09-22 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The mRNA Process Development & Manufacturing Summit will be taking place in-person in Boston, MA this month (September 20 – 22, 2022). The only conference roadmap to accelerate mRNA drug substance process scale up and manufacturing!
This conference will showcase the pioneering work of 30+ global leaders across 3 days of immersive content sharing new data, allowing you to stay ahead of the curve.
If you and your team are looking to learn how to overcome mRNA process scale up and manufacturing hurdles towards regulatory harmonization by optimizing in vitro transcription, purification, and analytical validation of your mRNA drug substance, then you should attend this dedicated industry forum to see the outlook to this advancing and dynamic field.
Multiple functions from 75+ leading companies and their teams have already registered, here’s just a snapchat:

Director – Business Development mRNA Therapeutics
Senior Director – Manufacturing Science & Technology
Head of Quality
Principal Applications Scientist – mRNA
Director – Formulation and Drug Delivery
Principal Scientist – Early Bioprocess
Senior Process Development Associate – mRNA
Group Leader (RNA Reagents) – Production
Downstream Scientist – Technical R&D
Scientist II – Analytical Development
Director – RNA Therapeutics Development R & D
Director – CMC RNA Vaccines Biopharmaceutical Development
Associate Director – Drug Substance
Senior Director – CMC Reg Affairs Regulatory

With very limited passes remaining, register today and be part of the conversation.
To know more visit: https://ter.li/9v5h9k

2nd NSCLC Drug Development Summit
2022-09-20 - 2022-09-22 | Boston, MA (venue TBC)
Advances in molecular and immunohistochemical techniques have ushered the NSCLC space into an exciting era of personalized medicine and improved outcomes – and a plethora of novel therapies are now in clinical development. Despite this, and whether patients fit into one of the actionable alteration subtypes of NSCLC or not, most will progress and/or develop resistance to currently available treatments.
NSCLC remains one of the highest tumor indications of unmet clinical need, with prevalence only set to increase. Focusing from late-line through to early-line, this conference will address how to supercharge your pipeline through implementing smart drug design; expert translational medicine; advanced trial design and patient recruitment; and evidence-based combination and sequencing rationale specific to NSCLC.
The 2nd NSCLC Drug Development Summit returns as the only industry-led forum for large biopharma, biotech and academic leaders to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication.
We will be focusing on:

Refining molecular testing of NSCLC tumors and making next-generation sequencing tools more accessible in the clinical setting
Investigating novel immune checkpoints and checkpoint inhibitor sequencing or combinations with surgery, chemo and/or radiotherapy where applicable, to define therapeutic options with better safety and efficacy outcomes in second line or beyond
Overcoming resistance mechanisms and patient progression after TKI treatment approaches for NSCLC tumors with actionable alterations
Providing clarity on tumor biopsy testing guidelines to promote effective personalized treatment of patients
Identifying truly transformative investigational drugs for use in the early vs. late-stage NSCLC setting and cut through the noise of increasingly complex therapeutic options
Exploring trial design challenges to watch out for and tips for patient inclusion/exclusion criteria

Join the NSCLC Summit for 3 jam-packed days of presentations, panel discussions and interactive workshops with over 20 expert industry speakers.
There has never been a more important time to rally together to defeat NSCLC and radically change patients lives.
To know more visit: https://bit.ly/3mpftud

Reuters Events: Cell & Gene Therapy USA 2022
2022-09-20 - 2022-09-21 | Virtual
Co-create a commercial toolkit that enables suitable, scalable and sustainable growth.
With over 20 CGTs projected to be approved by 2025, it’s clear that there are huge commercial and medical opportunities for precision medicine. But despite this unprecedented growth, unstable infrastructure, lack of standardization and novel scientific nuance means that there is still no industry blueprint for successful commercialization.
To realize this potential, precision medicine trailblazers must share lessons of launch success and overcome pain points to allow pharma to reinforce frameworks across manufacturing, market access and reimbursement to build infallible launch strategies across the board. Commercialization networks must go even further, transforming our healthcare system to guarantee scalable and sustainable growth.
Don’t get left behind.
Join us at Reuters Events: Cell and Gene Therapy USA where we have leaders from industry front runners to share their successes and pitfalls. With 30+ speakers, 5 case-studies and over 1500+ fellow CGT attendees – we will pioneer a new gold standard for commercialization, readying the world for CGT as a frontline treatment.
To know more visit: https://bit.ly/3oepDP3

Oligonucleotide Therapeutics and Delivery Conference 2022
2022-09-21 - 2022-09-22 | London, UK
Part of the 13th annual RNA Therapeutic series of events
SMi’s 2nd Annual Conference
Oligonucleotide Therapeutics and Delivery Conference 2022
Date: 21st – 22nd September 2022
Location: London, UK
Website: www.oligonucleotide.co.uk/PharmaJournalist
Advancements in extra-hepatic delivery of oligonucleotides
The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.
Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
Benefits of attending:

Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity
Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics

Plus, two interactive half day pre-conference workshops on 20th September 2022:

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge
Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting

CHAIRS FOR 2022:

Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
jimmy Weterings, Principal Scientist, AstraZeneca

FEATURED 2022 SPEAKERS INCLUDE:

Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals
SarahTabrizi,Director of UCL Huntington’s disease centre, UCL Institute of Neurology
Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
David Evans, Chief Scientific Officer, Sirnaomics
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator
Bart Anderson,Senior Director of R&D, Exicure

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers of:

RNA Biology/Discovery
Novel Therapeutic Modalities
Innovation Technologies
C-level Scientific Executives
Formulation and Drug Delivery
Clinical Research and Development
Cell Biology

EARLY-BIRD RATES:

BOOK BY 29TH APRIL AND SAVE £400
BOOK BY 31ST MAY AND SAVE £300
BOOK BY 30TH JUNE AND SAVE £200

Additional Contact Info:
T: +44 (0)20 7827 6154
E: ngaloria@smi-online.co.uk
LinkedIn: SMi Pharma
Twitter: @SMiPharma | #SMiOligonucleotides
Keywords:
Small interfering RNA, siRNA, Antisense therapy, DNA, RNA, nucleic acid, mRNA, Micro RNA, RNA-induced silencing complex, RISC, Aptamers, oligonucleotide, peptide molecules, Immunogenicity, Drug pipeline, short interfering RNA, silencing RNA, RNA interference, RNAi, mRNA degradation
Hashtags:
#SmallinterferingRNA, #siRNA, #Antisensetherapy, #DNA, #RNA, #nucleicacid, #mRNA, #MicroRNA, #RNAinducedsilencingcomplex, #RISC, #Aptamers, #oligonucleotide, #peptidemolecules, #Immunogenicity, #Drugpipeline, #shortinterferingRNA, #silencingRNA, #RNAinterference, #RNAi, #mRNAdegradation

4th RAS-Targeted Drug Development Summit
2022-09-26 - 2022-09-28 | Marriott Burlington, One Burlington Mall Road, Burlington, MA, 01803, United States
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is, in fact, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation.
The 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before, we will unite 300+ experts to showcase 3-days of exclusive, never shared before data as we delve into accelerating discovery and emerging strategies, optimizing translation and pre-clinical development, and advancing the landscape of clinical trials for combinations and monotherapies.
With mounting success in targeted RAS drugs, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need. Through novel data, expert insight, and exclusive discussions with global leaders, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C, G12D, and G12V. Continuing to advance valuable combination therapies into the clinic, and finally, crack resistance to RAS targeted therapeutics.
Access the official agenda for more information.
Early-bird & team discounts available – Secure your place today.

LEAP TA: Life Sciences 2022
2022-10-03 - 2022-10-05 | Embassy Suites by Hilton Boston at Logan Airport, 207 Porter St, Boston, MA, 02128, United States
The Definitive Event to Transform Your Internal Impact & Differentiate Your Employer Brand to Attract the in-Demand Biopharma Talent Required to Fast-Track Business Innovation & Growth
Now in its fourth year, LEAP TA: Life Sciences is the only forum dedicated to helping established and emerging life sciences organizations operating in the US who are breaking away from traditional TA to develop high functioning TA teams bursting to inspire talent needed to drive mission-critical innovation.
It is a unique opportunity to engage in a genuinely disruptive dialogue with your peers around what TA tech tools are really worth the investment and the radical new talent acquisition strategies required to address how life sciences organizations will deal with the fallout of the tight talent market in 2022 and beyond.
Designed for anyone with a stake in talent acquisition at the heart of biopharma businesses of all sizes, those who take part will find out how to rewrite the rules of talent acquisition to balance speed with fit in finding brilliant people to gain a sustainable competitive advantage.
So, whether you work in the newest start-up biotech or the largest big pharma company, there’s something at this event for you. Secure your place now to save time, money and add vital efficiencies to your talent acquisition activities.
To know more visit: https://bit.ly/3HO1Tdv

2nd Rare and Genetic Kidney Drug Development Summit
2022-10-04 - 2022-10-06 | Hilton Woburn, 2 Forbes Road, Woburn, MA, 01801, United States
Uniting industry experts dedicated to accelerating the frontier of transformative therapeutics, the 2nd Rare & Genetic Kidney Disease Drug Development Summit is the definitive industry forum sharing cross-industry insight to understand genetic drivers of disease, uncover early biomarkers of efficacy, and navigate disease specific endpoint development.
From clarifying molecular characteristics to reclassify disease subtypes to enrolling patient cohorts in rare disease populations, join industry experts in-person from Travere Therapeutics, FDA, Sanofi, Chinook Therapeutics, Goldfinch Bio, Takeda, Regulus Therapeutics, Otsuka and many more to accelerate life-changing therapeutics for the treatment of ADPKD, ARPKD, IgA, FSGS, Alport Syndrome.
To know more visit: https://ter.li/rzowfh

4th Macrophage-directed Therapies Summit
2022-10-04 - 2022-10-06 | Crowne Plaza Boston Woburn, 15 Middlesex Canal Park Dr, Woburn, MA, 01801, United States
4th Macrophage-directed Therapies Summit, taking place from 4-6 of October in Boston, will bring together professionals to accelerate the clinical validation of macrophage-directed therapies, manipulating and fixing phenotypic plasticity to develop safe, targeted therapies for oncology, autoimmunity, inflammation and beyond.
Join your peers in person and delve into:

CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery

You can view the event guide here: https://ter.li/ezyi0h
Secure your place at the summit here: https://ter.li/x9p0ua
We are looking forward to welcoming you to Boston this October!

2nd Annual Next Generation Pharmaceutical Cleanroom
2022-10-05 - 2022-10-06 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
2nd Annual Next Generation Pharmaceutical Cleanroom
5 – 6 October 2022
London, UK
http://www.nextgen-pharmacleanroom.com/PJwl
Sponsored by Ecolab, Elis Cleanroom, Innerspace, Microgenetics, Novatek
Co-Chaired by: Conor Murray, Chairman, Irish Cleanroom Society and Connor McMorrow, Aseptic Lead Cell Therapy, Takeda
Advances in Pharma 4.0 for an Improved, Efficient and Contaminant-Free Cleanroom
SAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
This one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals, biologicals, and cleanroom industry experts to explore hot topics within cleanroom design and engineering, best practices and regulation, environmental and contamination control, and pharmaceutical microbiology.
In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals, technological advancements in cleanrooms, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market.
This event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible, to the developments in technology that are enabling this to happen. Whether through robotics, automated disinfection, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry.
Event Hashtag: #PharmaCleanrooms
Key Reasons to attend:

Learn how to maximise the latest cleanroom technologies to modernise your contamination control strategy
Maximise the cost-effectiveness of your cleanroom and navigate best practises for cleanroom design
Optimise your preparation for upcoming regulatory changes, including the impending Annex 1
Increase your cleanroom availability & accessibility through streamlined approaches to contamination control

WHO SHOULD ATTEND:
Senior Micro Manager, QC Manager, Quality Director, Clean Room Design Managers, Design, Qualify and Testing – Clean Room (across the board), Head of Clean Room Technologies, Head of Compounding Pharmacies, Head of Clinical Drug Products, Head of Clinical Medical Device
View the brochure and to download visit http://www.nextgen-pharmacleanroom.com/PJwl

SAE Media Group's 3rd Annual Wearable Injectors and Connected Devices Conference
2022-10-10 - 2022-10-11 | London, UK
SAE Media Group’s 3rd Annual
Wearable Injectors and Connected Devices Conference
10 – 11 October 2022 | London, UK
http://www.wearable-injectors.co.uk/Pharmajournalist
The Latest Innovations In Digital Health And On-Body Drug Delivery For The Pharmaceutical Industry
SAE Media Group’s 3rd annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent, high volume and viscous drugs grow.
Benefits of Attending:

Engage with key regulatory updates surrounding digital health and medical devices
Discover advances in device design and development for large volume delivery via on-body injectors
Explore the key drivers of novel drug products for the development for on-body injectors
Hear insights into the growing potential of digital health to improve patient experience and treatment
Develop your understanding of design strategies for connectivity and digital health

Delegates will have the opportunity to network with the following companies:

Johnson & Johnson
Biogen
AstraZeneca
Merck KGaA
Novartis
Novo Nordisk
Boehringer Ingelheim

And many more!!
Who Should Attend:

Executives, Directors, VPs, Heads, Principals, Managers of:
Drug-Delivery Developers
Autoinjectors
Device Engineering
Human Factors
Injectables
Packaging
Regulatory Affairs
Connectivity
Medical Device Data
Novel Product Technology
Smart Device Developers
Device Safety Solution Providers
or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals, biotech, device developers and solution providers.

The two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity, and a platform for exchanging ideas.
For more information contact:
Nikisha Galoria | Marketing Executive | SAE Media Group
Email: ngaloria@smi-online.co.uk
Phone: +44 (0) 20 7827 6164
Follow us on:
LinkedIn: SAE Media Group Pharma
Twitter: @SAEMGPharma

Reuters Events: Pharma 2022
2022-10-11 - 2022-10-13 | Nice Acropolis Convention Center, Nice, France
Comprehensive frameworks for equitable access and accelerated digital transformations are soon to be realized. But progress is slowing, risking a return to the old model plagued by persistent health disparities.
To thrive, each strategy and tactic must be centred with a whole-human approach, ensuring an agile, patient-driven, technology-enabled change.
You must advance intelligent automation, delivering value-driven content that enhance patient and HCP experiences, activate new skillsets for field teams to strengthen clinical practices, whilst collaborating with stakeholders – and competitors – to drastically improve equitable access to the vast galaxy of innovation improving patient outcomes and propelling commercial growth.
Reuters Events: Pharma 2022 (11-13 October, Nice France – formerly eyeforpharma Barcelona) is the only place where patient experts, leading solution providers, and pharma changemakers – from commercial, marketing, medical affairs, patient engagement, market access and RWE – commit to business transformation as the catalyst for maximum patient impact.
To know more visit: https://bit.ly/3xVKqN8

10th IMPACCT Real World Evidence Summit
2022-10-11 - 2022-10-13 | Crowne Plaza Woburn, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Returning in person for its 10th year anniversary, the IMPACCT: Real World Evidence Summit will deep dive into the use of RWE for regulatory submissions and improved clinical trial design to help you navigate the regulatory landscape.
Following recent FDA and EMA guidelines, this comprehensive industry-led forum will address how drug developers can leverage RWE from beginning to end of study, ensure clinical studies are well-designed, include appropriate protections for their patients and upload data integrity.
Join 100+ senior leaders in RWE, RWD, real world analytics experts & epidemiologists from pharma and biotech to take part in this three day summit with over 18 hours of exclusive content.
To know more visit: https://ter.li/tymfzh

3rd Commercializing Flow Chemistry Summit 2022
2022-10-11 - 2022-10-13 | The Bostonian, 26 North St, Boston, MA, 02109, United States
With the exciting proof-of-concept milestones from Phlow, commitments from global regulatory agencies, and breakthroughs from the likes of AbbVie, AstraZeneca, Merck and BMS, over the last 12 months flow chemistry continues to take off at an exponential rate, further evidenced by the significant investments from CDMOs such as Almac, Corden Pharma, Sterling and Cambrex.
Showcasing the steep progress being made whilst addressing the field’s most front-of-mind challenges to enable the full potential of continuous chemistry to come to fruition, the 3rd Annual Commercializing Flow Chemistry Summit is back to bridge the gap between academic and industry innovation as your only meeting bringing both technical and strategic flow chemistry intelligence under one roof in Boston this October.
Uniting 100+ Process Development, Chemistry & Control, PAT, CMC, Continuous Manufacturing and Engineering experts across biopharma, academia, CDMO and fine chemical & API organizations for the first time in person, this is your prime opportunity to turn flow chemistry into industrial applications and implement advanced process control strategies to ensure product quality and meet regulatory expectations.
For practical takeaways across technical chemical engineering, process development, batch to flow transitions, novel chemistries, scale-up, PAT implementation & more, reduce your development cycle and enhance operational efficiency by attending the 3rd CFC Summit 2022!
To know more visit: https://ter.li/pqcevv

Innate Killer Summit Europe
2022-10-18 - 2022-10-20 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, and Macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through innate cell targeting and engineering.
Seize your chance to network with innate immune trailblazers from the likes of Sanofi, Takeda, Gamida Cell, Glycostem and Bayer and gain a comprehensive overview of candidates to inform your strategic development and progress the field together with an industry brain trust.
Bridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles, this is the must-attend meeting to accelerate safe and scalable therapies in Europe.
To learn more, visit: www.innate-killer-europe.com

Process Development for Cell Therapies Summit
2022-10-18 - 2022-10-20 | Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies

As momentum continues to build for the cell therapy industry, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods, maximize scalability and achieve regulatory compliance.
Join your peers who will all be gathering to learn how to identify and plug platform gaps for automation, global scale-out, faster phase development, increased affordability, and more!
With 20+ case studies being presented, you will come away with tried and tested strategies informed by industry leaders such as BMS, Kite, Lyell Immunopharma, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy, delivering case studies to provide actionable insights.
Now is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster.
Find out more about the meeting, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0
We look forward to welcoming you to Boston in October!

3rd Annual Gene Therapy Immunogenicity Summit
2022-10-18 - 2022-10-20 | The Colonade, 120 Huntington Ave, Boston, MA, 02116, United States
The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate, measure and predict the immune response to your gene therapy candidate.
In the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays.
Incorporating insights from leading immunological, bioanalytical, and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity.
With 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies.
To know more visit: https://ter.li/acp4lt

Operationalise: Early Access Programmes Summit Europe
2022-10-18 - 2022-10-20 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
With over 100 early and managed access, compassionate use, and named patient programmes running across the continent, the Operationalise: Early Access Programmes Summit Europe has been carefully curated to help you address difficulties with supply, logistics and cost, challenges with navigating European regulations, and planning and running equitable, patient-first early access programmes.
Download the full event guide to view the world-class speaker faculty of over 20 experienced EAP leaders, who will be sharing their insights through best-practice case studies.
Immerse yourself in three days of interactive sessions and discuss your peers’ approaches to involving the patient voice, engaging different stakeholders, planning considerations for a successful EAP and more.
With a specific focus on real-world case studies and practical applications, join us to gain a greater understanding and clarity of the end-to-end management of running an early access programme in Europe.

4th TIL Therapies Summit
2022-10-24 - 2022-10-26 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October in Boston, MA.
From preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones.
With 20+ world-class speakers and over 100 senior attendees from around the globe, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy!
Here’s your exclusive snapshot of the world class speaker faculty:

Michael Lotze, Chief Cellular Therapy Officer, Nurix Therapeutics
Mark Dudley, Chief Scientific Officer, InsTIL Bio
Daniel J Powell Jr, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
Parameswaran Hari, SVP Clinical Sciences, Iovance Biotherapeutics
Nick Restifo, Stealth Explorer, Immunotherapy
Karrie Wong, Director Cell Therapy, KSQ Therapeutics
Andrew Weinberg, Chief Scientific Officer, AgonOx
Jan Ter Meulen, Chief Scientific Officer, Obsidian Therapeutics
Tom Henley, Chief Scientific Officer, Intima Biosciences
Stephanie Woodall, Director – Head of Quality, KSQ Therapeutics
Sylvia Lee, Associate Professor, Program in Immunology Clinical Research Division, Fred Hutchinson Cancer Research Center
Ulrik Cordes, Founder & Chief Executive Officer, Cbio

Learn from pioneering trailblazers in TIL development from the National Cancer Institute & University of Pennsylvania alongside leading industry representatives from the likes of Iovance, Instil Bio and Obsidian Therapeutics.
As a host of developers look to bridge to the next generation of TIL therapies, now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development.
Join senior leaders from leading biotech, clinical and academic institutes to discuss data-driven and solution-based approaches to supercharge your TIL therapy towards commercialization.
To know more visit: https://ter.li/ygtovu

SAE Media Group’s 2nd Annual Biosensors for Medical Wearables
2022-10-24 - 2022-10-25 | Boston, MA, USA
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables
*In collaboration with Medical Design Briefs*
24th – 25th October 2022 | Boston, MA, USA
Sponsored by: Raumedic
http://www.biosensors-medical-wear.com/PJWL
Advances in development and therapeutic applications of on-body sensors
SAE Media Group is proud to present the Biosensors for Medical Wearables Conference, taking place on the 24th – 25th October 2022.

As part of SAE Media Group’s leading series of medical device conferences, this year’s event will be exploring the key drivers and innovations of the wearable medical biosensors landscape with insights into the latest technologies uncovering the therapeutic scope of medical biosensors and the potential of wearable sensors for decentralized diagnostic testing. With growing digital application, the 2022 agenda will also assess the potential of Artificial Intelligence coupled with sensors and understand how industry is managing digital outcomes.
Chairing the Conference this year will be industry giants James Mault, MD, Founder and CEO, BioIntelliSense, Inc and Andreas Caduff, Strategic Advisory Board, Digital Medicine Society (DiMe).
The featured 2022 speakers include:

Carrie Northcott, Director and Project Lead, Digital Medicine, and Translational Imaging (DMTI), Early Clinical Development (ECD), Pfizer, Inc
Eric Richardson, Vice President of Applied Research, MedRhythms, Inc.
Jennifer Goldsack, CEO, Digital Medicine Society (DiMe)
Samir Shah, Director, AstraZeneca
Tero-Pekka Alastalo, Chief Medical Officer and General Manager, US Operations, CardioSignal Inc
John Ralston, CEO and Founder, Neursantys, Inc.
Christine Guo, Chief Scientific c Officer, ActiGraph
Xina Quan, Co-Founder and CEO, PyrAmes, Inc.
Pierre-Alexandre Fournier, Co-founder/CEO, Hexoskin

Why should you attend?

You will explore the latest in biosensor technologies for wearable medical devices for therapeutics applications
You will uncover the potential of wearable sensors for decentralized diagnostic testing
You will delve into the evolving research and technologies to overcome unmet needs of the field including battery technologies for wearable sensors
You will assess the growing opportunities and sensor technologies being developed in industry for digital medicine and therapeutics
You will engage in platforms and opportunities for sensors coupled with AI and understand how industry are managing digital outcomes

Checkout the early bird offers:

BOOK BY 30TH JUNE AND SAVE $300
BOOK BY 31ST AUGUST AND SAVE $200

For more information please contact:
Nikisha Galoria | Marketing Executive | SAE Media Group
Email: ngaloria@smi-online.co.uk
Phone: +44 (0) 20 7827 6164
Follow us on:
LinkedIn: SAE Media Group Pharma
Twitter: @SAEMGPharma
#MedicalWearables

6th Annual Gene Therapy for Rare Disorders Europe Summit 2022
2022-10-25 - 2022-10-27 | London Marriott Hotel Regents Park, 128 King Henry’s Road, London, NW3 3ST, United Kingdom
As more and more companies gear up for clinical activity and near approval decisions, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever.
This year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share, experts in regulatory affairs, and the regulators themselves, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges.
Across three carefully curated days, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe.
To know more visit: https://bit.ly/3ysiVts

7th Annual Computational Drug Development (CDD) for Biologics Summit
2022-10-25 - 2022-10-27 | Boston Marriott Burlington, One Burlington Mall Road, Burlington, MA, 01803, United States
Returning to Boston this October, the 7th Annual Computational Drug Development (CDD) for Biologics Summit will continue to build on the reputation of past meetings while diving into the latest innovations in the industry. This year’s summit will highlight methods and best-practices to extrapolating data & leveraging deep learning for novel, complex biologics pipeline progression.
Across 3 days, we will unite leading experts including AbbVie, GSK, Amgen, Genentech, Takeda & many more to:

Overcome data availability and collection challenges to support machine learning and in silico drug discovery and development for biologics
Refine high throughput screening methods for novel antibody candidates to shorten your drug development cycles
Advance the next generation of computational biology in designing complex antibodies – including multifunctional, multi-specific antibodies
Empower the predictability of protein structures and protein-protein interactions for better drug development
Optimize your development cycle and decision making using computational data

Find out more – https://ter.li/ec2qbx

Protein Engineering Biocatalysis Congress
2022-10-26 - 2022-10-27 | Philadelphia, USA (venue TBC)
The Protein Engineering Biocatalysis Congress is the unique meeting point of industry, academia and service providers which will enable protein engineering and biocatalysis enthusiasts to industrialize sustainable enzyme products and increase product efficiency globally.
This event will highlight case studies on scaling up protein engineering technologies for commercial scale. It is your opportunity to analyze developments in protein engineering for biocatalysis to establish sustainable, scalable and cost-efficient API manufacturing.
To know more visit: www.proteinengineeringglobal.com

6th Dermatology Drug Development Summit
2022-11-01 - 2022-11-03 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall.
Ensure you join this year’s 150+ expert community in-person to:

Uncover recent studies evaluating critical inflammatory and auto-immune pathways
Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases
Assess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.
Obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa, Vitiligo, Rare Disease, and Alopecia Areata

View the event program here: https://ter.li/g3z67z
Register here: https://ter.li/vu3tx9
If you have any further questions regarding the summit, please contact us at info@hansonwade.com.

6th Microbiome Movement – Human Nutrition Summit
2022-11-07 - 2022-11-09 | TBC
Returning to Boston for 2022, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations, practical applications and clinical benefits of microbiome targeting food, beverages and supplements to pave the route to commercial success in the consumer health setting.
Get up to speed on this dynamic industry with expertise shared from the likes of Bayer, Postbiotics Plus, Amazentis and many others, as the titans of industry unite to:

Showcase the latest scientific findings on the mechanism and functional role of novel microbiome targeting ingredients
Shine a spotlight on the future of postbiotics, and advance commercialization of microbiome-targeted nutritional interventions
Advance commercialization of microbiome-targeted nutritional interventions

With consumers demanding to have greater control over personal health and wellbeing, join your community of 100+ industry experts from global CPG companies, innovative start-ups and biotechs to usher in a new wave of personalised nutrition.
To know more visit: https://bit.ly/3clIDZQ

6th Antifibrotic Drug Development Summit (AFDD)
2022-11-09 - 2022-11-11 | Crowne Plaza Woburn, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.
From exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ, cross-disease, cross-discipline discussion forum is here to transform your fibrosis research.
Join 100+ industry super giants from Boehringer Ingelheim, Genentech, Gilead, Pfizer, Novartis, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development.
To know more visit: https://ter.li/u60ni5

Medical Devices and IVD 2022
2022-11-14 - 2022-11-15 | London, UK
SAE Media Group’s Inaugural Conference…
Medical Devices and IVD 2022
14 – 15 November 2022
London, UK
www.medicaldevices-ivd.com/PJ
Navigating The MDR and IVDR and Best Strategies for Compliance
SAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference, taking place on 14 – 15 November 2022 in London, UK.

The MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry, bringing certain products into regulatory scope that were previously excluded, introducing new manufacturing requirements, and increasing the burden for post-market surveillance.
The conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition, the conference will consider the evolving regulatory landscape for digital health software.
BENEFITS OF ATTENDING:

Engage with notified body and competent authority representatives addressing key MDR and IVDR requirements
Gain insights from pharma regulatory experts in compliance and companion diagnostics
Understand the latest guidance on IVD Regulations to overcome common challenges, in addition to considering evolving global regulations
Examine post-market expectations for surveillance and vigilance of your medical devices
Delve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this

WHO SHOULD ATTEND:
Executives, Directors, VPs, Heads, Principals, Managers of:

Device Manufacturing
Regulatory Affairs
IVDR
MDR
CMC
Compliance
Risk Management
Traceability
Vigilance
Product Development
PFS
Combination Products

To find out more, please visit: www.medicaldevices-ivd.com/PJ
EARLY BIRD RATES:

BOOK BY 30TH JUNE TO SAVE £200
BOOK BY 30TH SEPTEMBER TO SAVE £100

ADDITIONAL CONTACT INFORMATION:

E: ngaloria@smi-online.co.uk
T: +44 (0) 20 7827 6164

FOLLOW US ON:

Twitter: @SAEMGPharma

LinkedIn: SAE Media Group Pharma
